Canadian researchers open a new front in the fight against MS
By Ross Neitz, University of Alberta
A discovery led by scientists at the University of Alberta and Ď㽶ĘÓƵ is providing hope of a new therapeutic target in Multiple Sclerosis (MS) patients, which could one day be used to prevent the symptoms and progression of the disease.
In examining donated human brain tissues, the researchers unexpectedly found that MS brains have extremely high content of a protein named calnexin, compared to those without MS. When the researchers tested the susceptibility of mice lacking calnexin to the mouse model of human MS (experimental autoimmune encephalomyelitis), they were astonished to find that the mice were completely resistant to the disease.
The causes of MS are not well understood. Symptoms vary widely but often include cognitive impairment, dizziness, tremors and fatigue. These problems are caused by a type of white blood cells called T-cells that, after becoming activated, find their way into the brain and attack the protective covering—myelin—of neurons in the brain and spinal cord, causing inflammation and damage to the central nervous system.
“It turns out that calnexin is somehow involved in controlling the function of the blood-brain barrier,” said Marek Michalak, a distinguished professor of biochemistry at the U of A. “This structure usually acts like a wall and restricts the passage of cells and substances from the blood into the brain. When there is too much calnexin, this wall gives angry T-cells access to the brain where they destroy myelin.”
Canada has one of the highest rates of MS in the world, with an estimated one in 340 Canadians living with the disease for which there are currently no known effective treatments.
“We think this exciting finding identifies calnexin as an important target for developing therapies for MS,” said Luis Agellon, a professor at the McGill School of Human Nutrition. “Our challenge now is to tease out exactly how this protein works in the cells involved in making up the blood-brain barrier. If we knew exactly what calnexin does in this process, then we could find a way to manipulate its function to promote resistance for developing MS.”
The study “” was published in , was funded by the Canadian Institutes of Health Research.
